
Vericel (VCEL) Stock Forecast & Price Target
Vericel (VCEL) Analyst Ratings
Bulls say
Vericel Corp's burn care franchise demonstrated strong performance with a 22% year-over-year growth, reaching $39.9 million in FY2024, driven by an expanded salesforce expected to sustain high single-digit growth in 2025. The company reported MACI revenue of $68.3 million in the fourth quarter of FY2024, marking a 21% increase year-over-year, showcasing its robust product pipeline with anticipated new launches, which are expected to further enhance revenue growth. Looking ahead, Vericel is guiding for approximately 20-23% revenue growth, supported by the positive momentum in MACI and the addition of NexoBrid to its portfolio, indicating a potential for profit inflection and favorable market conditions.
Bears say
Vericel Corp's financial performance shows signs of concern, as recent revenue results for both NexoBrid and Epicel fell short of expectations, indicating potential weaknesses in market demand. The company faced a top-line miss in its fourth quarter, reporting $75.4 million, which was beneath the anticipated range and highlights challenges in achieving growth in its critical product lines due to competitive pressures and market dynamics. Additionally, management noted that patient treatment conversions for Epicel were lower than expected, partially attributed to patient health issues, leading to a cautious outlook on future performance and profitability initiatives.
This aggregate rating is based on analysts' research of Vericel and is not a guaranteed prediction by Public.com or investment advice.
Vericel (VCEL) Analyst Forecast & Price Prediction
Start investing in Vericel (VCEL)
Order type
Buy in
Order amount
Est. shares
0 shares